About Vertex Pharmaceuticals Incorpor
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Vertex Pharmaceuticals Incorpor (VRTX) is a Healthcare company in the Biotechnology industry with a market capitalisation of $133.4B. The stock trades at 30.24x trailing earnings.
- Sector
- Healthcare
- Industry
- Biotechnology
- Market cap
- $133.4B
- P/E ratio
- 30.24
- Forward P/E
- 26.19
- EPS (TTM)
- $17.19
- Revenue (TTM)
- $12.6B
- Free cash flow
- $2.6B
- Profit margin
- 35.0%
- Beta
- 0.32
- Shares outstanding
- 253.5M
Financial health: Strong8.8/10
6 strengths, 0 concerns. No red flags against these benchmarks.
- Current ratio: 2.90 (Strong, benchmark > 1.5) — Short-term assets cover 2.90x short-term liabilities, against Graham's 1.5x floor. It has deteriorated over the last 4 years.
- Return on equity: 23.5% (Strong, benchmark > 15%) — Earns 23.5% on shareholder equity, comfortably past the > 15% mark.
- Gross margin: 55.0% (Strong, benchmark > 40%) — Keeps 55.0% of revenue after the direct cost of sales, comfortably past the > 40% mark.
- Net margin: 35.0% (Strong, benchmark > 10%) — Turns 35.0% of revenue into profit, comfortably past the > 10% mark.
- Free cash flow: $3.2B (Strong, benchmark positive) — Generated $3.2B of free cash flow after capital spending. It has deteriorated over the last 4 years.
- Revenue growth: 12.5% (Strong, benchmark > 10%) — Revenue changed 12.5% year on year, comfortably past the > 10% mark.
- Earnings growth: 8.0% (Watch, benchmark > 10%) — Earnings changed 8.0% year on year, short of the > 10% mark.
- PEG ratio: 1.90 (Watch, benchmark < 1) — At 1.90, the price looks fair relative to expected growth — Lynch treated 1.0 as fair value.